A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia
Study sponsor: Agios Pharmaceuticals, Inc. · AGIO
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-08-20Actual
Enrollment · participants20Actual
Source updated2026-03-30Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.